MiNK Therapeutics, Inc. (INKT) 10-Year Financial Performance & Capital Metrics

INKT • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

AboutMiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.Show more

Revenue $0
EBITDA -$10M +54.1%
Net Income -$11M +52.0%
EPS (Diluted) -2.80 +57.2%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -
ROIC -
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Shares diluted 12.4% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM10.34%

EPS CAGR

10Y-

5Y-

3Y-

TTM20.93%

ROCE

10Y Avg-939.7%

5Y Avg-939.7%

3Y Avg-1277.68%

Latest-

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	689.63K	0	0	0	0	0
Revenue Growth %	-	-1%	-	-	-	-
Cost of Goods Sold+	0	55.06K	77.96K	121.75K	204.62K	215.44K
COGS % of Revenue	-	-	-	-	-	-
Gross Profit+	689.63K	-55.06K	-77.96K	-121.75K	-204.62K	-215.44K
Gross Margin %	1%	-	-	-	-	-
Gross Profit Growth %	-	-1.08%	-0.42%	-0.56%	-0.68%	-0.05%
Operating Expenses+	22.97M	10.74M	18.53M	30.83M	22.72M	10.43M
OpEx % of Revenue	33.31%	-	-	-	-	-
Selling, General & Admin	3.83M	1.23M	4.56M	7.71M	7.43M	4.1M
SG&A % of Revenue	5.55%	-	-	-	-	-
Research & Development	19.65M	9.51M	13.97M	23.12M	15.49M	6.34M
R&D % of Revenue	28.5%	-	-	-	-	-
Other Operating Expenses	-508.07K	0	0	0	-204.62K	0
Operating Income+	-22.28M	-10.8M	-18.61M	-30.95M	-22.92M	-10.65M
Operating Margin %	-32.31%	-	-	-	-	-
Operating Income Growth %	-	0.52%	-0.72%	-0.66%	0.26%	0.54%
EBITDA+	-22.25M	-10.74M	-18.53M	-30.83M	-22.72M	-10.43M
EBITDA Margin %	-32.26%	-	-	-	-	-
EBITDA Growth %	-	0.52%	-0.72%	-0.66%	0.26%	0.54%
D&A (Non-Cash Add-back)	36.82K	55.06K	77.96K	121.75K	204.62K	215.44K
EBIT	-22.24M	-13.8M	-27.78M	-27.99M	-22.46M	-10.78M
Net Interest Income+	-1.56M	-2.44M	-2.43M	0	463.26K	172.57K
Interest Income	0	2.44K	2.43K	253.32K	463.26K	172.57K
Interest Expense	1.56M	2.44M	2.43M	253.32K	0	0
Other Income/Expense	-1.52M	-5.44M	-11.61M	2.96M	463.25K	-134.56K
Pretax Income+	-23.8M	-16.24M	-30.21M	-27.99M	-22.46M	-10.78M
Pretax Margin %	-34.51%	-	-	-	-	-
Income Tax+	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%
Net Income+	-23.8M	-16.24M	-30.21M	-27.99M	-22.46M	-10.78M
Net Margin %	-34.51%	-	-	-	-	-
Net Income Growth %	-	0.32%	-0.86%	0.07%	0.2%	0.52%
Net Income (Continuing)	-23.8M	-16.24M	-30.21M	-27.99M	-22.46M	-10.78M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0
EPS (Diluted)+	-10.80	-4.91	-9.03	-8.31	-6.54	-2.80
EPS Growth %	-	0.55%	-0.84%	0.08%	0.21%	0.57%
EPS (Basic)	-7.80	-4.91	-9.03	-8.31	-6.54	-2.90
Diluted Shares Outstanding	2.41M	3.31M	3.35M	3.37M	3.44M	3.86M
Basic Shares Outstanding	2.41M	3.31M	3.35M	3.37M	3.44M	3.74M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	918.4K	3.56M	39.63M	20.4M	3.6M	4.99M
Cash & Short-Term Investments	299.04K	2.69M	38.89M	19.64M	3.37M	4.58M
Cash Only	299.04K	2.69M	38.89M	19.64M	3.37M	4.58M
Short-Term Investments	0	0	0	0	0	0
Accounts Receivable	526K	254K	23K	0	0	0
Days Sales Outstanding	278.4	-	-	-	-	-
Inventory	87.7K	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-
Other Current Assets	-82.04K	120.58K	721.32K	470.3K	177.96K	164.24K
Total Non-Current Assets+	390.52K	997.38K	606.6K	1.07M	953.98K	732.93K
Property, Plant & Equipment	390.52K	458.38K	606.6K	1.07M	953.98K	732.93K
Fixed Asset Turnover	1.77x	-	-	-	-	-
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0
Other Non-Current Assets	0	539K	0	0	0	0
Total Assets+	1.31M	4.56M	40.24M	21.47M	4.55M	5.72M
Asset Turnover	0.53x	-	-	-	-	-
Asset Growth %	-	2.48%	7.83%	-0.47%	-0.79%	0.26%
Total Current Liabilities+	7.42M	14.22M	16.47M	12.68M	11.4M	6.96M
Accounts Payable	2.46M	3.14M	3M	5.82M	3.91M	2.73M
Days Payables Outstanding	-	20.83K	14.03K	17.46K	6.98K	4.62K
Short-Term Debt	0	0	0	0	0	0
Deferred Revenue (Current)	191.01K	0	0	0	0	0
Other Current Liabilities	3.08M	10.84M	5.76M	5.21M	5.66M	3.51M
Current Ratio	0.12x	0.25x	2.41x	1.61x	0.32x	0.72x
Quick Ratio	0.11x	0.25x	2.41x	1.61x	0.32x	0.72x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	30.22M	44.21M	0	9.19M	11.21M	18.35M
Long-Term Debt	26.79M	43.82M	0	0	0	4.92M
Capital Lease Obligations	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	3.43M	383.06K	0	9.19M	11.21M	13.42M
Total Liabilities	37.64M	58.43M	16.47M	21.87M	22.61M	25.31M
Total Debt+	26.79M	43.82M	0	0	0	4.92M
Net Debt	26.49M	41.13M	-38.89M	-19.64M	-3.37M	347.57K
Debt / Equity	-	-	-	-	-	-
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-
Interest Coverage	-14.28x	-4.42x	-7.65x	-122.17x	-	-
Total Equity+	-36.33M	-53.87M	23.78M	-401.3K	-18.06M	-19.59M
Equity Growth %	-	-0.48%	1.44%	-1.02%	-43.99%	-0.08%
Book Value per Share	-15.09	-16.28	7.10	-0.12	-5.25	-5.07
Total Shareholders' Equity	-36.33M	-53.87M	23.78M	-401.3K	-18.06M	-19.59M
Common Stock	241	87	335	339	346	40
Retained Earnings	-36.5M	-52.74M	-82.95M	-110.94M	-133.4M	-144.18M
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	-132.59K	-1.52M	-625.27K	-292.47K	-430.95K	-631.58K
Minority Interest	0	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-14.94M	-8.34M	-12.83M	-18.87M	-15.76M	-9.56M
Operating CF Margin %	-21.67%	-	-	-	-	-
Operating CF Growth %	-	0.44%	-0.54%	-0.47%	0.16%	0.39%
Net Income	-23.8M	-16.24M	-30.21M	-27.99M	-22.46M	-10.78M
Depreciation & Amortization	36.82K	55.06K	77.96K	121.75K	204.62K	215.44K
Stock-Based Compensation	219.57K	87.83K	1.74M	3.03M	3.86M	1.81M
Deferred Taxes	0	0	0	0	0	0
Other Non-Cash Items	4.49M	8.08M	11.83M	-2.79M	-266.78K	-1.26M
Working Capital Changes	4.12M	-324.93K	3.74M	8.77M	2.9M	459.73K
Change in Receivables	0	1.8M	0	0	0	0
Change in Inventory	0	-1.8M	0	0	0	0
Change in Payables	886.67K	607.86K	-152.04K	2.66M	-1.92M	-1.18M
Cash from Investing+	-426.47K	-95.21K	-248.98K	-250.05K	-73.56K	0
Capital Expenditures	-426.47K	-95.21K	-248.98K	-250.05K	-73.56K	0
CapEx % of Revenue	0.62%	-	-	-	-	-
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0
Cash from Financing+	11.44M	11.11M	49.26M	-155.6K	-407.17K	10.82M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	0	0	150	1.59K	70.47K	19.99K
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-15.37M	-8.43M	-13.08M	-19.12M	-15.84M	-9.56M
FCF Margin %	-22.29%	-	-	-	-	-
FCF Growth %	-	0.45%	-0.55%	-0.46%	0.17%	0.4%
FCF per Share	-6.38	-2.55	-3.91	-5.68	-4.61	-2.47
FCF Conversion (FCF/Net Income)	0.63x	0.51x	0.42x	0.67x	0.70x	0.89x
Interest Paid	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-127.07%	-239.5%	-	-
Gross Margin	100%	-	-	-	-	-
Net Margin	-3451.46%	-	-	-	-	-
Interest Coverage	-14.28x	-4.42x	-7.65x	-122.17x	-	-
FCF Conversion	0.63x	0.51x	0.42x	0.67x	0.70x	0.89x
Revenue Growth	-	-100%	-	-	-	-

Frequently Asked Questions

Growth & Financials

MiNK Therapeutics, Inc. (INKT) grew revenue by 0.0% over the past year. Growth has been modest.

MiNK Therapeutics, Inc. (INKT) reported a net loss of $12.4M for fiscal year 2024.

Dividend & Returns

MiNK Therapeutics, Inc. (INKT) had negative free cash flow of $1.35B in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener